Andrea L. Cathcart

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Edward Gane, Wai Kay Seto, Henry Lik‐Yuen Chan et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 546 citations

Pharmacy, Infectious Diseases, Pharmacology +12

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Ann M. Arvin, Katja Fink, Michael Schmid et al. · Nature · 2020 · 537 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Kosh Agarwal, Maurizia Rossana Brunetto, Wai Kay Seto et al. · Journal of Hepatology · 2018 · 423 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +10

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez et al. · JAMA · 2022 · 294 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +12

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

Andrea L. Cathcart, Colin Havenar‐Daughton, Florian A. Lempp et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 254 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14